Scholarlink

Background and Objective <p>Intraperitoneal lidocaine is an emerging strategy for analgesia following abdominal surgery but its pharmacokinetics are poorly quantified. We aimed to develop a pharmacokinetic model for unbound and total lidocaine by intraperitoneal and intravenous routes.</p> Methods <p>Unbound and total lidocaine concentrations, and pain scores (visual analogue score 0–10) were from a published randomized control trial of adults (<i>n&#xa0;</i>=&#xa0;56) undergoing laparoscopic colon resection. Participants received intravenous or intraperitoneal lidocaine (2&#xa0;mg/kg bolus then 1.5&#xa0;mg/kg/h infusion) for 72&#xa0;h postoperatively. Data were pooled with literature-derived alpha-1-acid glycoprotein concentrations (AAG) to support total lidocaine modelling. Unbound kinetics were described using compartmental models with first order absorption between intraperitoneal and plasma compartments. A turnover model described AAG kinetics with constant binding to lidocaine. An inhibitory pharmacodynamic model was explored to link concentration to pain scores. </p> Results <p>Maximum lidocaine concentrations after intraperitoneal administration were means (range) of 3.0 (0.4–4.5)&#xa0;mg/L total and 0.6 (0.1–0.9)&#xa0;mg/L unbound. Intraperitoneal absorption was incomplete (bioavailability&#xa0;=&#xa0;0.66, 95% confidence interval (CI) 0.6–0.76) with a half-time of 0.5 (0.4–0.8) h. A two-compartment model with first order elimination fit best, with unbound clearance 121 (108–136)&#xa0;L/h/70&#xa0;kg. The binding constant to AAG (<i>K</i><sub>D</sub>) was 2.98 (2.69–3.35)&#xa0;µmol/L. A pharmacodynamic model with <i>C</i><sub>50</sub> of 0.21&#xa0;mg/L and maximal reduction (<i>E</i><sub>max</sub>) of 6 units captured pain scores and was used to simulate dosing strategies.</p> Conclusions <p>A third of the intraperitoneal dose did not reach the central compartment and absorption took ~2&#xa0;h. Simulations show that 2&#xa0;mg/kg/h intraperitoneal infusion achieves a 5-point pain score reduction within ~36&#xa0;min.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacokinetics of Intraperitoneal Lidocaine for Sustained Postoperative Analgesia in Adults

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Kenyon W. Osborne,
  • Wiremu S. MacFater,
  • Brian J. Anderson,
  • Darren Svirskis,
  • Andrew G. Hill,
  • Jacqueline A. Hannam

摘要

Background and Objective

Intraperitoneal lidocaine is an emerging strategy for analgesia following abdominal surgery but its pharmacokinetics are poorly quantified. We aimed to develop a pharmacokinetic model for unbound and total lidocaine by intraperitoneal and intravenous routes.

Methods

Unbound and total lidocaine concentrations, and pain scores (visual analogue score 0–10) were from a published randomized control trial of adults (n = 56) undergoing laparoscopic colon resection. Participants received intravenous or intraperitoneal lidocaine (2 mg/kg bolus then 1.5 mg/kg/h infusion) for 72 h postoperatively. Data were pooled with literature-derived alpha-1-acid glycoprotein concentrations (AAG) to support total lidocaine modelling. Unbound kinetics were described using compartmental models with first order absorption between intraperitoneal and plasma compartments. A turnover model described AAG kinetics with constant binding to lidocaine. An inhibitory pharmacodynamic model was explored to link concentration to pain scores.

Results

Maximum lidocaine concentrations after intraperitoneal administration were means (range) of 3.0 (0.4–4.5) mg/L total and 0.6 (0.1–0.9) mg/L unbound. Intraperitoneal absorption was incomplete (bioavailability = 0.66, 95% confidence interval (CI) 0.6–0.76) with a half-time of 0.5 (0.4–0.8) h. A two-compartment model with first order elimination fit best, with unbound clearance 121 (108–136) L/h/70 kg. The binding constant to AAG (KD) was 2.98 (2.69–3.35) µmol/L. A pharmacodynamic model with C50 of 0.21 mg/L and maximal reduction (Emax) of 6 units captured pain scores and was used to simulate dosing strategies.

Conclusions

A third of the intraperitoneal dose did not reach the central compartment and absorption took ~2 h. Simulations show that 2 mg/kg/h intraperitoneal infusion achieves a 5-point pain score reduction within ~36 min.